Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE-2: AXS-05 for Alzheimer's Disease Agitation
NCT05557409Phase 3Completed
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Sep 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of dextromethorphan + bupropion in agitation, sponsored by Axsome Therapeutics, Inc.. Started Sep 2022; status: completed.
02
Drugs
dextromethorphan + bupropion
03
Conditions
agitation
Beyond the preview
Go deeper on NCT05557409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05557409.